Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 10/20 | 0.66 |
| ▸ | IP6K3 | Q96PC2 | 5/20 | 0.66 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.66 |
| ▸ | PARP1 | P09874 | 8/20 | 0.63 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066634 | 0.87 | PARP1 (0.58) | IP6K1IP6K3IP6K2PARP1CHEK1 | |
| SCHEMBL7427860 | 0.85 | IP6K1 (0.68) | IP6K1IP6K3IP6K2PARP1CHEK1 | |
| SCHEMBL9911097 | 0.83 | IP6K1 (0.66) | IP6K1IP6K3IP6K2PARP1CHEK1 | |
| SCHEMBL496967 | 0.83 | IP6K1 (0.65) | IP6K1IP6K3IP6K2PARP1CHEK1 | |
| SCHEMBL17080826 | 0.82 | IP6K1 (0.64) | IP6K1IP6K3IP6K2PARP1CHEK1 | |
| SCHEMBL8170598 | 0.81 | IP6K1 (0.71) | IP6K1IP6K3IP6K2PARP1CHEK1 | |
| SCHEMBL27947190 | 0.81 | IP6K1 (0.62) | IP6K1IP6K3IP6K2PARP1CHEK1 | |
| SCHEMBL28224560 | 0.80 | IP6K1 (0.62) | IP6K1IP6K3IP6K2PARP1CHEK1 | |
| SCHEMBL22042406 | 0.80 | IP6K1 (0.61) | IP6K1IP6K3IP6K2PARP1CHEK1 | |
| SCHEMBL20334906 | 0.80 | IP6K1 (0.61) | IP6K1IP6K3IP6K2PARP1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2022-09-15 | — | — | US | disclosed |
| EP-4010334-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | Novartis AG (CH) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028806-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | WDR5, WDR77, WDR1 | IP6K1 1097/4885IP6K3 1145/4885IP6K2 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.